Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, has received clearance from the US Food and Drug Administration (FDA) to implement protocol amendments for its ongoing clinical trial for HT-001. 

The drug is being developed as a potential treatment for cancer patients experiencing skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRI).

The clinical trial, conducted under Hoth's open Investigational New Drug Application (IND) for HT-001, aims to evaluate the efficacy, safety, and tolerability of the drug in treating EGFRI-induced skin toxicity. HT-001 is a gel formulation designed to address the adverse skin effects associated with cancer treatments.

Robb Knie, Chief Executive Officer of Hoth Therapeutics, expressed satisfaction with the FDA clearance and emphasized the company's commitment to delivering a safe and effective treatment for this underserved patient population. He stated, "These latest developments underscore Hoth Therapeutics' continued commitment to delivering a safe and effective treatment for this very underserved patient population."

The Phase 2a dose-ranging study is a randomized, double-blind, placebo-controlled, multi-center trial. It includes adult patients (≥ 18 years of age) undergoing EGFRI therapy. The study is divided into two cohorts: an open-label cohort to measure pharmacokinetics and a randomized, parallel arm study to compare three dose strengths of HT-001 gel to placebo.

In the randomized cohorts, patients will be assigned to one of four treatment arms in a 2:2:2:1 ratio (active groups = 2: placebo = 1). All patients in both open-label and blinded cohorts will apply the study drug once a day to each affected area, with up to 30 percent body surface area involvement, including skin, scalp, and nails.

The goal of the study is to determine the minimum efficacious dose strength(s) for further investigation. Evaluation will include dose effects, application site safety assessments, and therapeutic effects based on primary and secondary endpoints.

The positive initial data and a clean safety profile to date have contributed to Hoth Therapeutics' optimism about the potential benefits of HT-001 for patients undergoing cancer treatment with EGFRI. The protocol amendments aim to optimize the clinical trial and generate a robust dataset to support the treatment's efficacy and safety.